The redesigned follitropin α pen injector for infertility treatment

Bibliography

• Boivin J, Bunting L, Collins JA, International estimates of infertility prevalence and treatment-seeking: potential need and demand for infertility medical care. Hum Reprod 2007;22:1506-12
   PubMed Web of Science ®Google Scholar
• GONAL-f 1050 IU/1.75 ml (77 mcg/1.75 ml) SPC. Available from: http://emc.medicines.org.uk/document.aspx?documentId=12227#POSOLOGY [Last accessed 18 January 2010]
   Google Scholar
• Papanikolaou EG, Kolibianakis E, Devroey P. Emerging drugs in assisted reproduction. Expert Opin Emerg Drugs 2005;10:425-40
   PubMedGoogle Scholar
• Homburg R. Management of infertility and prevention of ovarian hyperstimulation in women with polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 2004;18:773-88
   PubMed Web of Science ®Google Scholar
• Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update 2002;8:559-77
   PubMed Web of Science ®Google Scholar
• Olivennes F, Frydman R. Friendly IVF: the way of the future? Hum Reprod 1998;13:1121-4
   PubMed Web of Science ®Google Scholar
• Markle RL, King PJ, Martin DB, Characteristics of successful human chorionic gonadotropin (hCG) administration in assisted reproduction (abstract). Fertil Steril 2002;78:S71-2
   Web of Science ®Google Scholar
• Quintans CJ, Donaldson MJ, Blanco LA, Empty follicle syndrome due to human errors: its occurrence in an in-vitro fertilization programme. Hum Reprod 1998;13:2703-5
   PubMed Web of Science ®Google Scholar
• Esposito MA, Patrizio P. Partial follicular aspiration for salvaging an IVF cycle after improper hCG administration. A case report. J Reprod Med 2000;45:511-14
   PubMed Web of Science ®Google Scholar
• Dahlgren J. Easypod: a new electronic injection device for growth hormone. Expert Rev Med Devices 2008;5:297-304
   PubMed Web of Science ®Google Scholar
• EN ISO 11608-1:2000. Pen-injectors for medical use - Part 1: Pen-injectors - Requirements and test methods. Available from: http://www.iso.org/iso/catalogue_detail.htm?csnumber=19545 [Last accessed 12 August 2010]
   Google Scholar
• Bohannon NJ. Insulin delivery using pen devices. Simple-to-use tools may help young and old alike. Postgrad Med 1999;106:57-8, 61-4, 68
   PubMed Web of Science ®Google Scholar
• Brunton S. Initiating insulin therapy in type 2 diabetes: benefits of insulin analogs and insulin pens. Diabetes Technol Ther 2008;10:247-56
   PubMed Web of Science ®Google Scholar
• Hanestad BR, Albrektsen G. Quality of life, perceived difficulties in adherence to a diabetes regimen, and blood glucose control. Diabet Med 1991;8:759-64
   PubMed Web of Science ®Google Scholar
• Pfutzner A, Asakura T, Sommavilla B, Insulin delivery with FlexPen: dose accuracy, patient preference and adherence. Expert Opin Drug Deliv 2008;5:915-25
   PubMed Web of Science ®Google Scholar
• Asakura T, Jensen KH. Comparison of intuitiveness, ease of use, and preference in two insulin pens. J Diabetes Sci Technol 2009;3:312-19
   PubMedGoogle Scholar
• Reimer T, Hohberg C, Pfutzner AH, Intuitiveness, instruction time, and patient acceptance of a prefilled insulin delivery device and a reusable insulin delivery device in a randomized, open-label, crossover handling study in patients with type 2 diabetes. Clin Ther 2008;30:2252-62
   PubMed Web of Science ®Google Scholar
• Kivitz A, Cohen S, Dowd JE, Clinical assessment of pain, tolerability, and preference of an autoinjection pen versus a prefilled syringe for patient self-administration of the fully human, monoclonal antibody adalimumab: the TOUCH trial. Clin Ther 2006;28:1619-29
   PubMed Web of Science ®Google Scholar
• Aghssa MM, Azargoon A, Ramezanzadeh F, A comparison of the efficacy, tolerability, and convenience of two formulations of follitropin-alpha in Iranian woman undergoing intracytoplasmic sperm injection cycles. Fertil Steril 2008;90:1043-8
   PubMed Web of Science ®Google Scholar
• Rama Raju GA, Suryanarayana K, Jaya PG, Comparison of follitropin-beta administered by a pen device with conventional syringe in an ART programme - a retrospective study. J Clin Pharm Ther 2008;33:401-7
   PubMed Web of Science ®Google Scholar
• Sedbon E, Wainer R, Perves C. Quality of life of patients undergoing ovarian stimulation with injectable drugs in relation to medical practice in France. Reprod Biomed Online 2006;12:298-303
   PubMed Web of Science ®Google Scholar
• Somkuti SG, Schertz JC, Moore M, Patient experience with follitropin alfa prefilled pen versus previously used injectable gonadotropins for ovulation induction in oligoanovulatory women. Curr Med Res Opin 2006;22:1981-96
   PubMed Web of Science ®Google Scholar
• Weiss N. Gonadotrophin products: empowering patients to choose the product that meets their needs. Reprod Biomed Online 2007;15:31-7
   PubMed Web of Science ®Google Scholar
• Porter R, Kissel C, Saunders H, Patient and nurse evaluation of recombinant human follicle-stimulating hormone administration methods: comparison of two follitropin injection pens. Curr Med Res Opin 2008;24:727-35
   PubMed Web of Science ®Google Scholar
• GONAL-f RFF, NDA no. 021765. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseactionSearch.Label_ApprovalHistory#apphist [Last accessed 31 March 2011]
   Google Scholar
• Butler PA, Khanna J. Assisted reproduction in developing countries. Facing up to the issues. Progress Reprod Health Res 2003;63:1
   Google Scholar
• Oddens BJ, den Tonkelaar I, Nieuwenhuyse H. Psychosocial experiences in women facing fertility problems–a comparative survey. Hum Reprod 1999;14:255-61
   PubMed Web of Science ®Google Scholar
• Huisman D, Raymakers X, Hoomans EH. Understanding the burden of ovarian stimulation: fertility expert and patient perceptions. Reprod Biomed Online 2009;19(Suppl 2):5-10
   PubMedGoogle Scholar